Kwality Pharmaceuticals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY24Mar 2024FY23Mar 2023
+22.4%−45.0%
+10.5%−64.9%
+3.9%−71.8%
—−84.1%
+11.5%+4.1%
+11.8%—
—−33.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

KPL₹3,696.70

Kwality Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Revenue Growth—-45.0+22.4
EBITDA Growth—-64.9+10.5
EBIT Growth—-71.8+3.9
EPS Growth—-84.1—
Total Assets Growth—+4.1+11.5
Total Equity Growth——+11.8
Cash from Operations Growth—-33.1—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.